Statin Use and the Risk of Graves’ Orbitopathy: A Nationwide Population-Based Cohort Study
Authors' conclusion
The use of statins in Asian GD patients was associated with a reduced risk of GO. In addition, the risk of developing GO among users of commonly prescribed statins or users of different intensities of statins was not significantly different.
Study context
- Population
- Graves' disease (GD) patients aged >40 years, Taiwan National Health Insurance Research Database (NHIRD) 2010–2020
- Participants
- 102,858 patients
- Exposure
- Statin users vs nonusers
- Statin usersn = 7,073
- Nonusersn = 95,785reference
- Outcome
- Risk of GO
Methodological detailsnationwide, population-based, propensity score matching, IPTW
- Nationwide
- Population-based
- Propensity score matching
- IPTW
Main finding
As reported in the abstract
GO
Each group vs nonusersEstimate (95% CI)P value
Statin users
adjusted HR (PS matching) 0.79(0.63–0.99)
P = 0.037Statin users
adjusted HR (IPTW) 0.64(0.51–0.79)
P < 0.001Observational data: associations, not effects.
Further findings
‰
| Outcome | Statin users | Nonusers |
|---|---|---|
| Crude incidence rate of GO, overall population | 5.00 | 6.75 |
| Crude incidence rate of GO, after PS matching | 4.91 | 5.15 |
Graves' orbitopathy (GO) risk by statin type and intensity
- Risk of GO not different among statin types (atorvastatin, rosuvastatin, pitavastatin, other) or intensities (low-to-moderate vs high)
Original publication
Statin Use and the Risk of Graves’ Orbitopathy: A Nationwide Population-Based Cohort Study. Thyroid. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →